text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 10238-21-8 | Product Number: G0382

Glibenclamide


Purity: >98.5%(T)(HPLC)
Synonyms:
  • 5-Chloro-N-[4-(3-cyclohexylureidosulfonyl)phenethyl]-2-methoxybenzamide
  • Glyburide
Product Documents:
5G
$38.00
4   Contact Us ≥40 
25G
$85.00
4   1   ≥40 

* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.


Product Number G0382
Purity / Analysis Method >98.5%(T)(HPLC)
Molecular Formula / Molecular Weight C__2__3H__2__8ClN__3O__5S = 494.00 
Physical State (20 deg.C) Solid
Storage Temperature Refrigerated (0-10°C)
Condition to Avoid Heat Sensitive
CAS RN 10238-21-8
Reaxys Registry Number 2230085
PubChem Substance ID 135726994
Merck Index (14) 4478
MDL Number

MFCD00056625

Specifications
Appearance White to Almost white powder to crystal
Purity(HPLC) min. 98.5 area%
Purity(Neutralization titration) min. 98.5 %
Melting point 172.0 to 176.0 °C
Properties (reference)
Melting Point 174 °C
Solubility in water Insoluble
Solubility (soluble in) Dimethylformamide
Solubility (slightly sol. in) Ethanol, Methanol
GHS
Related Laws:
RTECS# YS4725200
Transport Information:
HS Number 2930.90.2900
Application
Glibenclamide: A Sulfonylurea ATP-Dependent K+ Channel Antagonist

Glibenclamide belongs to sulfonylurea antidiabetics which increase the release of insulin from pancreatic B-cells. Sulfonylurea antidiabetics inhibit ATP-gated K+ channels and thereby cause depolarization of the B-cell membrane. The depolarization leads to activation of voltage-dependent Ca channels and Ca2+ influx into the B-cell, and eventually increases insulin release. Recently, a combination agent with metformin [M2009] is also used for the treatment of Type 2 diabetes. (The product is for research purpose only.)

References


PubMed Literature


TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The product with the lot number searched for has been discontinued and no related documentation is available.

Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.

A sample C of A for this product is not available at this time.

Analytical Charts
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The requested analytical chart is not available. Sorry for the inconvenience.

The product with the lot number searched for has been discontinued and no related documentation is available.

Other Documents

Session Status
Your session will timeout in 10 minutes. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page. minute. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page.

Your session has timed out. You will be redirected to the HOME page.